[1]

Aw DZH, Zhang DX, Vignuzzi M. 2025. Strategies and efforts in circumventing the emergence of antiviral resistance against conventional antivirals. npj Antimicrobials and Resistance 3:54

doi: 10.1038/s44259-025-00125-z
[2]

Nature Microbiology. 2024. Considering the host in host–pathogen interactions. Nature Microbiology 9:1149−49

doi: 10.1038/s41564-024-01708-8
[3]

Chen B, Yu P, Chan WN, Xie F, Zhang Y, et al. 2024. Cellular zinc metabolism and zinc signaling: from biological functions to diseases and therapeutic targets. Signal Transduction and Targeted Therapy 9:6

doi: 10.1038/s41392-023-01679-y
[4]

Read SA, Obeid S, Ahlenstiel C, Ahlenstiel G. 2019. The role of zinc in antiviral immunity. Advances in Nutrition 10:696−710

doi: 10.1093/advances/nmz013
[5]

Jothimani D, Kailasam E, Danielraj S, Nallathambi B, Ramachandran H, et al. 2020. COVID-19: poor outcomes in patients with zinc deficiency. International Journal of Infectious Diseases 100:343−49

doi: 10.1016/j.ijid.2020.09.014
[6]

Santos HO. 2022. Therapeutic supplementation with zinc in the management of COVID-19–related diarrhea and ageusia/dysgeusia: mechanisms and clues for a personalized dosage regimen. Nutrition Reviews 80:1086−1093

doi: 10.1093/nutrit/nuab054
[7]

Briassoulis G, Briassoulis P, Ilia S, Miliaraki M, Briassouli E. 2023. The anti-oxidative, anti-inflammatory, anti-apoptotic, and anti-necroptotic role of zinc in COVID-19 and sepsis. Antioxidants 12:1942

doi: 10.3390/antiox12111942
[8]

Chu A, Foster M, Ward S, Zaman K, Hancock D, et al. 2015. Zinc-induced upregulation of metallothionein (MT)-2A is predicted by gene expression of zinc transporters in healthy adults. Genes & Nutrition 10:44

doi: 10.1007/s12263-015-0494-y
[9]

Kwon CS, Kountouri AM, Mayer C, Gordon MJ, Kwun IS, et al. 2007. Mononuclear cell metallothionein mRNA levels in human subjects with poor zinc nutrition. The British Journal of Nutrition 97:247−254

doi: 10.1017/S0007114507328614
[10]

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, et al. 2021. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71

doi: 10.1136/bmj.n71
[11]

Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, et al. 2016. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919

doi: 10.1136/bmj.i4919
[12]

Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, et al. 2011. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343:d5928

doi: 10.1136/bmj.d5928
[13]

Ren X, Wen W, Fan X, Hou W, Su B, et al. 2021. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell 184:1895−913.e19

doi: 10.1016/j.cell.2021.01.053
[14]

Wolf FA, Angerer P, Theis FJ. 2018. SCANPY: large-scale single-cell gene expression data analysis. Genome Biology 19:15

doi: 10.1186/s13059-017-1382-0
[15]

Sauerwald N, Zhang Z, Ramos I, Nair VD, Soares-Schanoski A, et al. 2022. Pre-infection antiviral innate immunity contributes to sex differences in SARS-CoV-2 infection. Cell Systems 13:924−31.e4

doi: 10.1016/j.cels.2022.10.005
[16]

Budhraja A, Basu A, Gheware A, Abhilash D, Rajagopala S, et al. 2022. Molecular signature of postmortem lung tissue from COVID-19 patients suggests distinct trajectories driving mortality. Disease Models & Mechanisms 15:dmm049572

doi: 10.1242/dmm.049572
[17]

Fang Z, Liu X, Peltz G. 2023. GSEApy: a comprehensive package for performing gene set enrichment analysis in Python. Bioinformatics 39:btac757

doi: 10.1093/bioinformatics/btac757
[18]

Futschik ME, Carlisle B. 2005. Noise-robust soft clustering of gene expression time-course data. Journal of Bioinformatics and Computational Biology 3:965−88

doi: 10.1142/S0219720005001375
[19]

Mahjoub L, Youssef R, Yaakoubi H, Ben Salah H, Jaballah R, et al. 2024. Melatonin, vitamins and minerals supplements for the treatment of Covid-19 and Covid-like illness: a prospective, randomized, double-blind multicenter study. Explore 20:95−100

doi: 10.1016/j.explore.2023.06.009
[20]

Thomas S, Patel D, Bittel B, Wolski K, Wang Q, et al. 2021. Effect of high-dose zinc and ascorbic acid supplementation vs usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection: the COVID A to Z randomized clinical trial. JAMA Network Open 4:e210369−e69

doi: 10.1001/jamanetworkopen.2021.0369
[21]

Ben Abdallah S, Mhalla Y, Trabelsi I, Sekma A, Youssef R, et al. 2023. Twice-daily oral zinc in the treatment of patients with coronavirus disease 2019: a randomized double-blind controlled trial. Clinical Infectious Diseases 76:185−191

doi: 10.1093/cid/ciac807
[22]

Patel O, Chinni V, El-Khoury J, Perera M, Neto AS, et al. 2021. A pilot double-blind safety and feasibility randomized controlled trial of high-dose intravenous zinc in hospitalized COVID-19 patients. Journal of Medical Virology 93:3261−3267

doi: 10.1002/jmv.26895
[23]

Ibrahim Alhajjaji G, Alotaibi N, Abutaleb N, Alotaibi MM, Alhajjaji A, et al. 2023. Effect of zinc supplementation on symptom reduction and length of hospital stay among pediatric patients with Coronavirus disease 2019 (COVID-19). Saudi Pharmaceutical Journal 31:585−591

doi: 10.1016/j.jsps.2023.02.011
[24]

Al Sulaiman K, Aljuhani O, Al Shaya AI, Kharbosh A, Kensara R, et al. 2021. Evaluation of zinc sulfate as an adjunctive therapy in COVID-19 critically ill patients: a two center propensity-score matched study. Critical Care 25:363

doi: 10.1186/s13054-021-03785-1
[25]

Carlucci PM, Ahuja T, Petrilli C, Rajagopalan H, Jones S, et al. 2020. Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients. Journal of Medical Microbiology 69:1228−1234

doi: 10.1099/jmm.0.001250
[26]

Maret W, Krezel A. 2007. Cellular zinc and redox buffering capacity of metallothionein/thionein in health and disease. Molecular Medicine 13:371−375

doi: 10.2119/2007-00036.Maret
[27]

Subramanian Vignesh K, Deepe GS, Jr. 2017. Metallothioneins: emerging modulators in immunity and infection. International Journal of Molecular Sciences 18:2197

doi: 10.3390/ijms18102197
[28]

Sato M, Sasaki M, Hojo H. 1994. Differential induction of metallothionein synthesis by interleukin-6 and tumor necrosis factor-α in rat tissues. International Journal of Immunopharmacology 16:187−195

doi: 10.1016/0192-0561(94)90075-2
[29]

Ling XB, Wei HW, Wang J, Kong YQ, Wu YY, et al. 2016. Mammalian metallothionein-2A and oxidative stress. International Journal of Molecular Sciences 17:1483

doi: 10.3390/ijms17091483
[30]

Butcher HL, Kennette WA, Collins O, Zalups RK, Koropatnick J. 2004. Metallothionein mediates the level and activity of nuclear factor kappa B in murine fibroblasts. The Journal of Pharmacology and Experimental Therapeutics 310:589−598

doi: 10.1124/jpet.104.066126
[31]

Saletta F, Suryo Rahmanto Y, Noulsri E, Richardson DR. 2010. Iron Chelator-mediated alterations in gene expression: identification of novel iron-regulated molecules that are molecular targets of hypoxia-inducible factor-1α and p53. Molecular Pharmacology 77:443−458

doi: 10.1124/mol.109.061028
[32]

Kim CH, Kim JH, Lee J, Ahn YS. 2003. Zinc-induced NF-κB inhibition can be modulated by changes in the intracellular metallothionein level. Toxicology and Applied Pharmacology 190(2):189−196

doi: 10.1016/s0041-008x(03)00167-4
[33]

Stafford SL, Bokil NJ, Achard MES, Kapetanovic R, Schembri MA, et al. 2013. Metal ions in macrophage antimicrobial pathways: emerging roles for zinc and copper. Bioscience Reports 33:e00049

doi: 10.1042/BSR20130014
[34]

Liu Y, Liu H, Chen W, Yang T, Zhang W. 2014. EOLA1 protects lipopolysaccharide induced IL-6 production and apoptosis by regulation of MT2A in human umbilical vein endothelial cells. Molecular and Cellular Biochemistry 395:45−51

doi: 10.1007/s11010-014-2110-7
[35]

Mussbacher M, Salzmann M, Brostjan C, Hoesel B, Schoergenhofer C, et al. 2019. Cell type-specific roles of NF-κB linking inflammation and thrombosis. Frontiers in Immunology 10:85

doi: 10.3389/fimmu.2019.00085
[36]

Fekete R, Simats A, Bíró E, Pósfai B, Cserép C, et al. 2025. Microglia dysfunction, neurovascular inflammation and focal neuropathologies are linked to IL-1- and IL-6-related systemic inflammation in COVID-19. Nature Neuroscience 28:558−576

doi: 10.1038/s41593-025-01871-z
[37]

Beckers M, Bloem BR, Helmich RC. 2023. Mask on, mask off: subclinical Parkinson's disease unveiled by COVID-19. Journal of Movement Disorders 16:55−58

doi: 10.14802/jmd.22067
[38]

Padmanabhan P, Desikan R, Dixit NM. 2020. Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection. PLoS Computational Biology 16:e1008461

doi: 10.1371/journal.pcbi.1008461
[39]

Hashimoto R, Sakamoto A, Deguchi S, Yi R, Sano E, et al. 2021. Dual inhibition of TMPRSS2 and Cathepsin Bprevents SARS-CoV-2 infection in iPS cells. Molecular Therapy Nucleic Acids 26:1107−1114

doi: 10.1016/j.omtn.2021.10.016
[40]

Zhao MM, Yang WL, Yang FY, Zhang L, Huang WJ, et al. 2021. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduction and Targeted Therapy 6:134

doi: 10.1038/s41392-021-00558-8
[41]

van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere T, et al. 2020. Presence of genetic variants among young men with severe COVID-19. JAMA 324:663−673

doi: 10.1001/jama.2020.13719
[42]

Wang C, Khatun MS, Ellsworth CR, Chen Z, Islamuddin M, et al. 2024. Deficiency of Tlr7 and Irf7 in mice increases the severity of COVID-19 through the reduced interferon production. Communications Biology 7:1162

doi: 10.1038/s42003-024-06872-5
[43]

Lynes MA, Hidalgo J, Manso Y, Devisscher L, Laukens D, et al. 2014. Metallothionein and stress combine to affect multiple organ systems. Cell Stress and Chaperones 19:605−611

doi: 10.1007/s12192-014-0501-z
[44]

Duprez J, Roma LP, Close AF, Jonas JC. 2012. Protective antioxidant and antiapoptotic effects of ZnCl2 in rat pancreatic islets cultured in low and high glucose concentrations. PLoS One 7:e46831

doi: 10.1371/journal.pone.0046831
[45]

Borchert S, Suckrau PM, Walter RFH, Wessolly M, Mairinger E, et al. 2020. Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma. Scientific Reports 10:18677

doi: 10.1038/s41598-020-75807-x
[46]

Tarapore P, Shu Y, Guo P, Ho SM. 2011. Application of phi29 motor pRNA for targeted therapeutic delivery of siRNA silencing metallothionein-IIA and survivin in ovarian cancers. Molecular Therapy 19:386−394

doi: 10.1038/mt.2010.243
[47]

Racioppo B, Pechalrieu D, Abegg D, Dwyer B, Ramseier NT, et al. 2025. Chemoproteomics-enabled de novo proteolysis targeting chimera discovery platform identifies a metallothionein degrader to probe its role in cancer. Journal of the American Chemical Society 147:7817−7828

doi: 10.1021/jacs.4c17827